To foster robust business growth in today’s rapidly evolving marketplace, companies should wholeheartedly embrace the indispensable role of market research reports. The X Linked Hypophosphatemia (XLH) ...
FREMONT, Calif., Sept. 3, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with ...
X-linked hypophosphatemia is a hereditary renal phosphate-wasting disorder characterized by hypophosphatemia, rickets and/or osteomalacia, and diminished growth. Phosphate levels are low because ...
X-linked hypophosphatemia (XLH), also known as hereditary type I hypophosphatemia (HPDR I) or familial hypophosphatemia, is an inherited, chronic condition that causes your body to lose phosphate.
LOS ALTOS, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today ...
Please provide your email address to receive an email when new articles are posted on . Patients with chronic kidney disease on maintenance dialysis experienced improved control of hyperphosphatemia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results